FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of (177)Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma

PURPOSE: (177)Lu-lilotomab satetraxetan targets the CD37 antigen and has been investigated in a first-in-human phase 1/2a study for relapsed non-Hodgkin lymphoma (NHL). Tumor dosimetry and response evaluation can be challenging after radioimmunotherapy (RIT). Changes in FDG PET/CT parameters after R...

Descripción completa

Detalles Bibliográficos
Autores principales: Løndalen, Ayca, Blakkisrud, Johan, Revheim, Mona-Elisabeth, Madsbu, Ulf Erik, Dahle, Jostein, Kolstad, Arne, Stokke, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113302/
https://www.ncbi.nlm.nih.gov/pubmed/33196921
http://dx.doi.org/10.1007/s00259-020-05098-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113302/
https://www.ncbi.nlm.nih.gov/pubmed/33196921
http://dx.doi.org/10.1007/s00259-020-05098-x

Ejemplares similares